Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II Study Combining CD24Fc With Checkpoint Inhibitors for Patients With Metastatic Melanoma

Next Previous
Trial Profile

Phase Ib/II Study Combining CD24Fc With Checkpoint Inhibitors for Patients With Metastatic Melanoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 May 2021 Status changed from not yet recruiting to withdrawn prior to enrolment due to business reasons.
  • 11 Feb 2021 Planned initiation date changed from 15 Jan 2021 to 15 Jun 2021.
  • 22 Nov 2020 Number of arms changed from 3 to 1. Experimental arm: Renal Cell Carcinoma and Colon cancer are removed from study protocol. Study design changed from Parallel Assignment to Single Group Assignment. Allocation changed from Non-Randomized to N/A. Disease conditions renal cell carcinoma or colon cancer are removed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top